



Stabilis



Glycopyrronium bromide



Noms commerciaux

Glycopyrronium bromide injection	Grande Bretagne
Robinul	Autriche, Belgique, Etats Unis d'Amérique, Finlande, Norvège, Suède



Stabilité des solutions

	∅	0,2 mg/ml	25°C		90		1756
	∅	0,2 mg/ml	4°C		90		1756








































Stabilité en mélange

	∅	0,1 mg/ml	25°C	?	Palonosetron hydrochloride : 25 µg/ml	4	2286
PVC	▲	15 mg/ml	21°C		Haloperidol lactate : 52 mg/ml Buprenorphine hydrochloride : 57 mg/ml	30	2113
PVC	▲	15 mg/ml	36°C		Haloperidol lactate : 52 mg/ml Buprenorphine hydrochloride : 57 mg/ml	9	2113
PVC	▲	15 mg/ml	4°C		Haloperidol lactate : 52 mg/ml Buprenorphine hydrochloride : 57 mg/ml	30	2113
PP	▲	15 mg/ml	21°C		Haloperidol lactate : 52 mg/ml Buprenorphine hydrochloride : 57 mg/ml	30	2113
PP	▲	0,1 mg/ml	23°C		Ondansetron hydrochloride : 1 mg/ml	24	815
PP	▲	15 mg/ml	36°C		Haloperidol lactate : 52 mg/ml Buprenorphine hydrochloride : 57 mg/ml	16	2113
PP	▲	15 mg/ml	4°C		Haloperidol lactate : 52 mg/ml Buprenorphine hydrochloride : 57 mg/ml	30	2113
PP	▲	0,1 mg/ml	4°C		Ondansetron hydrochloride : 1 mg/ml	24	815



Compatibilités

			
	Glycopyrronium bromide Butorphanol tartrate		3599
	Glycopyrronium bromide : 0.2 mg/ml Cimetidine hydrochloride : 150 mg/ml		1438
	 Glycopyrronium bromide Dexamethasone sodium phosphate		3668
	 Glycopyrronium bromide Diazepam		3599
	 Glycopyrronium bromide Dimenhydrinate		3599
	Glycopyrronium bromide Droperidol		3599
	Glycopyrronium bromide Fentanyl citrate		3599
	Glycopyrronium bromide Lorazepam		3599
	 Glycopyrronium bromide Methohexital sodium		3599
	Glycopyrronium bromide : 0.1 mg/ml Midazolam hydrochloride : 2.5 mg/ml	∅	404
	Glycopyrronium bromide Morphine sulfate		3599
	Glycopyrronium bromide : 0,2 mg/ml Neostigmine methylsulfate : 0,5 mg/ml	∅	2286
	Glycopyrronium bromide Neostigmine methylsulfate		3599
	Glycopyrronium bromide : 0.1 mg/ml Ondansetron hydrochloride : 1 mg/ml		815
	Glycopyrronium bromide : 0.07 & 0.11 mg/ml Oxycodone hydrochloride : 14.7 & 38.5 mg/ml		2900
	Glycopyrronium bromide : 0.07 & 0.11 mg/ml Oxycodone hydrochloride : 14.7 & 38.5 mg/ml		2900
	Glycopyrronium bromide : 0,2 mg/ml Palonosetron hydrochloride : 50 µg/ml	∅	2286
	 Glycopyrronium bromide Pentobarbital sodium		3599
	Glycopyrronium bromide Pethidine hydrochloride		3599
	Glycopyrronium bromide Promethazine hydrochloride		3599
	 Glycopyrronium bromide : 0.2 mg/ml Propofol		660
	Glycopyrronium bromide : 0.2 mg/ml Propofol : 10 mg/ml	∅	300
	Glycopyrronium bromide : 0,2 mg/ml Ranitidine hydrochloride : 25 mg/ml	∅	58
	 Glycopyrronium bromide Thiopental sodium		3599



Voie d'administration




Bibliographie

	Type	Source
58	Revue	Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm 1985 ; 38: 160-161.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
404	Revue	Forman JK, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987 ; 44: 2298-2299.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
815	Revue	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL. Stability of ondansetron hydrochloride and 12 medications in plastic syringes. Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
1438	Revue	Souney PF, Solomon MA, Stancher D. Visual compatibility of cimetidine hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1984 ; 41: 1840-1841.
1756	Revue	Storms ML, Stewart JT, Flynn WW. Stability of glycopyrrolate injection at ambient temperature and 4°C in polypropylene syringes. Int J Pharm Compound 2003 ; 7: 65-67.
2113	Revue	Jäppinen A, Kokki H, Naaranlahti TJ, Rasi AS. Stability of buprenorphine, haloperidol and glycopyrrolate mixture in a 0.9% sodium chloride solution. Pharm World Sci 1999 ; 21, 6: 272-274.
2286	Revue	Ben M, Trusley C, Kupiec TC, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 4: 368-371.
2900	Revue	Hines S, Pleasance S. Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration. EJHP 2009 ; 15, 5: 32-38.
3599	Laboratoire	Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics Amco Amdipharm Mercy 2013
3668	Laboratoire	Dexamethasone - Summary of Product Characteristics Hospira 2015

Stabilis



Glycopyrronium bromide



Stabilité des préparations

50 mg ® = ?		Horizon pharmaceutical	Eau du robinet 100 ml	24-26°C		25		2833
10 mg ® = ?		SyrSpend SF® >> 20 ml	25°C		90		4198	
10 mg ® = ?		SyrSpend SF® >> 20 ml	4°C		90		4198	
30 mg ® = ? (Corepharma)		OraPlus® / OraSweet® (1:1) >> 60 ml	23-25°C		90		3203	
30 mg ® = ? (Corepharma)		OraPlus® / OraSweet SF® (1:1) >> 60 ml	23-25°C		90		3203	
20 mg ® = ?		OraPlus® / OraSweet® (1:1) >> 100 ml	25°C		14		3856	
20 mg ® = ?		Methylcellulose 1% / Sirop simple (1:1) >> 100 ml	25°C		14		3856	
20 mg ® = ?		OraPlus® / OraSweet® (1:1) >> 100 ml	25°C		14		3856	
20 mg ® = ?		Methylcellulose 1% / Sirop simple (1:1) >> 100 ml	25°C		14		3856	
50 mg		Sorbitol 10 g Tampon phosphate 0.05M pH 5.6 >> 100 ml	24-26°C		129		2834	
50 mg		Saccharose 10 g Tampon phosphate 0.05M pH 5.6 >> 100 ml	24-26°C		129		2834	



Facteur influençant la stabilité

	PH < 6			2833
	PH = 7			2834




































Bibliographie

	Type	Source
2833	Revue	Das Gupta V. Stability of an Oral Liquid Dosage Form of Glycopyrrolate Prepared from Tablets Int J Pharm Compound 2001 ; 5, 6: 480-481.
2834	Revue	Das Gupta V. Stability of Oral Liquid Dosage Forms of Glycopyrrolate Prepared With the Use of Powder Int J Pharm Compound 2003 ; 7, 5: 386-388.
3203	Revue	Cober MP, Johnson CE, Sudekum D, Penprase K Stability of extemporaneously prepared glycopyrrolate oral suspensions. Am J Health-Syst Pharm 2011 ; 68:843-845.
3856	Revue	Nahata M.C. Long-term Stability of Zonisamide, Amitriptyline, and Glycopyrrolate in Extemporaneously Prepared Liquid-dosage Forms at Two Temperatures Int J Pharm Compound 2016 ; 20, 2:164-166.
4198	Revue	Uriel M, Gomez-Rincon C, Marro D. Stability of regularly prescribed oral liquids formulated with SyrSpend® SF. Pharmazie 2018 73;196-201



Dictionnaire

 Antimuscarinique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Seringue polypropylène
 Aucun	 Lumière
 Jour	 A l'abri de la lumière
 Stabilité en mélange	 Solvant
 Molécule	 Verre
 Non précisée	 Heure
 Polyvinyl chlorure	 Chlorure de sodium 0,9%
 Polypropylène	 Compatibilités
 Compatible	 Incompatibilité non précisée
 Incompatible	 Eau pour préparation injectable
 Instabilité de l'émulsion à 4 heures	 Voie d'administration
 Intraveineuse	 Intramusculaire
 Sous cutanée	 Perfusion SC continue
 Bibliographie	 Solution buvable
 Stabilité des préparations	 Origine
 Excipient	 Comprimés
 Poudre	 Flacon plastique
 Non précisé	 Facteur influençant la stabilité
 Provoque	 Augmentation stabilité
 Dégradation	 Dictionnaire